Literature DB >> 17077981

[Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?].

J Pausch1, M Gatzen.   

Abstract

The clinical-biochemical syndrome of cholestasis is characterized by an alteration in bile constituents. As a consequence, the concentrations of bilirubin, bile acids, phospholipids and cholesterol are elevated. The main clinical symptoms of cholestasis are icterus and pruritus, and in severe cases xanthelasma and xanthoma. Primary intrahepatic cholestasis, caused by impaired bile secretion in the liver, should be separated from the extrahepatic secondary cholestasis which is a consequence of a biliary obstruction. This paper evaluates the therapy of liver diseases which developed as consequence of a primary disturbance in bile secretion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077981     DOI: 10.1007/s00108-006-1732-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

Review 1.  Hepatic overlap syndromes.

Authors:  Ulrich Beuers
Journal:  J Hepatol       Date:  2004-12-13       Impact factor: 25.083

Review 2.  Primary biliary cirrhosis.

Authors:  Marshall M Kaplan; M Eric Gershwin
Journal:  N Engl J Med       Date:  2005-09-22       Impact factor: 91.245

3.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Authors:  M Leuschner; K P Maier; J Schlichting; S Strahl; G Herrmann; H H Dahm; H Ackermann; J Happ; U Leuschner
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.

Authors:  C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

Review 6.  Hepatic secretion of conjugated drugs and endogenous substances.

Authors:  D Keppler; J König
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Cholestatic syndromes.

Authors:  Michael Trauner; James L Boyer
Journal:  Curr Opin Gastroenterol       Date:  2003-05       Impact factor: 3.287

Review 8.  Primary biliary cirrhosis.

Authors:  Jayant A Talwalkar; Keith D Lindor
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

9.  Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

Authors:  R E Poupon; R Poupon; B Balkau
Journal:  N Engl J Med       Date:  1994-05-12       Impact factor: 91.245

Review 10.  Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.